Detalhe da pesquisa
1.
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Ann Oncol
; 31(12): 1746-1754, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32866624
2.
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification.
Ann Oncol
; 31(3): 440-441, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32067689
3.
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario.
ESMO Open
; 7(2): 100406, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35219245
4.
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
ESMO Open
; 6(2): 100078, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33735802
5.
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.
Clin Transl Oncol
; 22(6): 844-851, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392645
6.
Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406].
ESMO Open
; 7(2): 100471, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35378403
7.
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078].
ESMO Open
; 6(3): 100137, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34144775
8.
Latency as a region contrast: Measuring ERP latency differences with Dynamic Time Warping.
Psychophysiology
; 52(12): 1559-76, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26372033
9.
Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile.
Leukemia
; 32(2): 543-546, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28924243